ACCS and metabolic disease: In conclusion, numbers of commercially available ACCs inhibitors have exhibited strong therapeutic effects on disease models in vivo and in vitro, supporting that ACCs are promising therapeutic targets for the treatment of tumour and metabolic diseases.